ChanTest has added the capability to perform a bioassay in conformance with cGMP. The in vitro assay involves higher throughput Ussing chamber experiments for measuring inhibition of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) chloride ion channel short circuit current, a measure of chloride ion secretion. ChanTest recently passed its first regulatory inspection related to this bioassay.
The new testing capability allows the company to offer cGMP bioassays for release of natural products (i.e., botanicals) and any drug working via ion channels, GPCRs or transporter targets.
Arthur "Buzz" Brown, M.D., Ph.D., chief executive officer at ChanTest, said, "ChanTest is extremely excited to bring this unique cGMP testing service to the pharma community. This means that we can now partner with pharma and biotech companies to bring safe medicines to market from the beginning to the very end of the drug development process."